Cipla chief calls for ‘obligatory’ drug licensing

August 16, 2013 08:55 pm | Updated June 13, 2016 09:46 am IST - London:

Yusuf Hamied, chairman of Cipla, said he was confident a Canadian system, which allows the country to copy any drug as long as it pays four per cent royalties to the patent holder, would be the best way forward for India. File Photo.

Yusuf Hamied, chairman of Cipla, said he was confident a Canadian system, which allows the country to copy any drug as long as it pays four per cent royalties to the patent holder, would be the best way forward for India. File Photo.

The Chairman of pharmaceutical firm Cipla has asked the Indian government to push for ‘obligatory licensing’ of drugs to improve access to essential medicines in the Third World.

Yusuf Hamied, often referred to as the grand old man of the Indian pharmaceutical industry, was here to propagate his vision of Indian companies being free to manufacture and market drugs at an affordable cost.

“It is important to have a compulsory licensing system. In fact, I am in favour of obligatory licensing where we don’t mind paying royalties to the patent holder but at least Indian companies should be able to manufacture and market essential drugs to make them more accessible ,” he said.

He said he was confident a Canadian system, which allows the country to copy any drug as long as it pays four per cent royalties to the patent holder, would be the best way forward for India.

Mr. Hamied, who stepped down as Cipla’s Managing Director earlier this year , said: “What is good enough for the Canadians, should be good enough for the Indians.

“There is big obsolescence in the drugs industry and new drugs are coming up all the time. We don’t want to encroach on the regulated developed world markets of the world. Just leave the developing world to us so that we don’t deprive millions and ensure access to affordable drugs.”

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.